62 related articles for article (PubMed ID: 17434254)
1. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors.
Kassouf W; Spiess PE; Brown GA; Munsell MF; Grossman HB; Siefker-Radtke A; Dinney CP; Kamat AM
Eur Urol; 2007 Sep; 52(3):769-74. PubMed ID: 17434254
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer.
Li R; Naidu S; Fan W; Rose K; Huelster H; Grass GD; Vosoughi A; Dhillon J; Kim Y; Gupta S; Jain RK; Zhang J; Zemp L; Yu A; Poch MA; Spiess PE; Pow-Sang J; Gilbert SM; Sexton WJ
Urol Oncol; 2023 Nov; 41(11):457.e17-457.e24. PubMed ID: 37880002
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of tumor ureteral invasion on recurrence after radical cystectomy.
Saito T; Matsumoto K; Tanaka N; Fukumoto K; Yasumizu Y; Takeda T; Morita S; Kosaka T; Mizuno R; Asanuma H; Hara S; Oya M
Int Urol Nephrol; 2024 Jan; 56(1):129-135. PubMed ID: 37731158
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis.
Kimura S; Mari A; Foerster B; Abufaraj M; Vartolomei MD; Stangl-Kremser J; Karakiewicz PI; Egawa S; Shariat SF
J Urol; 2019 Jan; 201(1):46-53. PubMed ID: 30077559
[TBL] [Abstract][Full Text] [Related]
5. Predictive models of long-term survival outcomes following radical cystectomy.
Ohtsu A; Arai S; Fujizuka Y; Miyazawa Y; Nomura M; Sekine Y; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Cancer Med; 2023 Dec; 12(23):21118-21128. PubMed ID: 37902172
[TBL] [Abstract][Full Text] [Related]
6. Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway.
Møller CT; Tafjord G; Blindheim A; Berge V; Fosså S; Andreassen BK
Scand J Urol; 2023 Nov; 58():101-108. PubMed ID: 37953521
[TBL] [Abstract][Full Text] [Related]
7. Comparison of partial and total cystectomy for colorectal cancer with histologically confirmed bladder invasion.
Suh JW; Kim DW; Lee J; Yang IJ; Ahn HM; Oh HK; Kim JK; Lee H; Oh JJ; Lee S; Jeong SJ; Hong SK; Byun SS; Kang SB
Surgery; 2024 Jun; ():. PubMed ID: 38851902
[TBL] [Abstract][Full Text] [Related]
8. Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer.
Mori K; Matsumoto K; Ikeda M; Koguchi D; Shimizu Y; Tsumura H; Ishii D; Tsuji S; Sato Y; Iwamura M
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835810
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
Lu L; Chen C; Cheng H; Ding H; Tian J; Wang H; Wang Z
BMC Cancer; 2023 Nov; 23(1):1066. PubMed ID: 37932689
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience.
Serrano M; Muñoz-Unceta N; Alonso LA; Azueta A; Gutiérrez Baños JL; Ferreira L; Domínguez M; Torres Zurita A; Ballestero R; Cacho D; López-Brea M; Sotelo M; Campos-Juanatey F; Ramos Barseló E; Duran I
Clin Transl Oncol; 2024 Feb; 26(2):549-553. PubMed ID: 37566343
[TBL] [Abstract][Full Text] [Related]
11. Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Culine S; Harter V; Krucker C; Gravis G; Fléchon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Fontugne J; Allory Y; Pfister C;
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980628
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy.
Rodler S; Buchner A; Eismann L; Schulz GB; Marcon J; Ledderose S; Schlenker B; Stief CG; Karl A; Jokisch JF
Res Rep Urol; 2022; 14():281-290. PubMed ID: 35937307
[TBL] [Abstract][Full Text] [Related]
13. Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View.
Mazzucchelli R; Marzioni D; Tossetta G; Pepi L; Montironi R
Front Surg; 2021; 8():754741. PubMed ID: 34926567
[TBL] [Abstract][Full Text] [Related]
14. Multiple brain metastases in a patient with ypT0N0 micropapillary urothelial carcinoma of the bladder.
Kuppa S; Wei J; Strother M; Miyamoto C; Weaver M; Kutikov A
Urol Case Rep; 2021 Nov; 39():101838. PubMed ID: 34631426
[TBL] [Abstract][Full Text] [Related]
15. Multicenter external validation of the radical cystectomy pentafecta in a European cohort of patients undergoing robot-assisted radical cystectomy with intracorporeal urinary diversion for bladder cancer.
Baron P; Khene Z; Lannes F; Pignot G; Bajeot AS; Ploussard G; Verhoest G; Gasmi A; Perrot O; Roumiguie M; Mori K; Cacciamani GE; Rouprêt M; Bruyère F; Pradere B
World J Urol; 2021 Dec; 39(12):4335-4344. PubMed ID: 34216242
[TBL] [Abstract][Full Text] [Related]
16. Dataset for the reporting of carcinoma of the bladder-cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).
Compérat E; Srigley JR; Brimo F; Delahunt B; Koch M; Lopez-Beltran A; Reuter V; Samaratunga H; Shanks JH; Tsuzuki T; van der Kwast T; Varma M; Webster F; Grignon D
Virchows Arch; 2020 Apr; 476(4):521-534. PubMed ID: 31915958
[TBL] [Abstract][Full Text] [Related]
17. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens.
Mari A; Kimura S; Foerster B; Abufaraj M; D'Andrea D; Hassler M; Minervini A; Rouprêt M; Babjuk M; Shariat SF
BJU Int; 2019 Jan; 123(1):11-21. PubMed ID: 29807387
[TBL] [Abstract][Full Text] [Related]
19. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
Guancial EA; Kilari D; Xiao GQ; Abu-Farsakh SH; Baran A; Messing EM; Kim ES
PLoS One; 2016; 11(5):e0155503. PubMed ID: 27187160
[TBL] [Abstract][Full Text] [Related]
20. The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy.
Parker WP; Ho PL; Boorjian SA; Melquist JJ; Thapa P; Holzbeierlein JM; Frank I; Kamat AM; Lee EK
World J Urol; 2016 Nov; 34(11):1561-1566. PubMed ID: 26943643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
